SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is surging as part of a broad semiconductor rally that traders link to expectations that agentic AI adoption, sparked by Meta's Muse agent, will sharply lift data-center CPU demand, with heavy call-option buying and short-covering chatter amplifying the move. Bulls frame it as the start of a CPU demand cycle and a validating turnaround, while skeptics call the rally an overextended pump in a still-unprofitable company.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Shares are surging to record highs, briefly lifting AMD past the $1 trillion market-cap milestone for the first time amid a broad semiconductor rally. Retail traders are split between bulls celebrating the trillion-dollar club entry and pressing for more upside, and skeptics calling the move overextended on stretched valuations, with some taking profits or shorting into strength.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk shares slid sharply following its Capital Markets Day, where management laid out targets of more than five multi-blockbuster launches by 2030 but guided revenue growth only in line with pharma peers, leaving concerns over semaglutide patent expirations and Eli Lilly's competitive pressure unresolved. The community is split, with many traders calling the single-digit-P/E stock oversold and buying the dip or calls while others fault CEO Mike Doustdar's messaging and want aggressive M&A—even a positive CagriSema head-to-head readout against tirzepatide in type 2 diabetes did little to lift sentiment.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X ETF

A steep slide in the 3x inverse semiconductor ETF as chip stocks rallied is dominating the conversation, with dip-buyers aggressively averaging down while frustrated holders lament heavy losses. The board is split between bears betting the AI-semiconductor bubble deflatesciting a hawkish Fed, rising yields and oil, and AI-slowdown warningsand critics arguing the chip rally has further to run, alongside frequent complaints about leveraged-ETF decay and alleged market manipulation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is moving higher as traders position for upcoming fiscal Q2 earnings, with analyst previews from RBC and CIBC suggesting revenue could top consensus and that guidance may be raised. Sentiment is split between bulls citing QNX's physical AI momentum  including the Sift telemetry partnership and anticipated Alloy Kore design wins  and bears shorting the rally while flagging management share sales and skepticism about revenue growth.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals is surging after the U.S. reached a security agreement with Denmark and Greenland, which traders view as de-risking and potentially accelerating its Tanbreez rare earth project ahead of U.S.-China talks where critical minerals are on the agenda. Community reaction is split between bulls expecting a short squeeze given elevated short interest and skeptics calling the move a sell-the-news event for a pre-revenue developer whose processing capacity remains years away.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is rallying sharply amid a broader risk-on crypto rally, with traders focused on whether it can push through a heavily discussed round-number resistance level near current prices. Bulls see the volume-backed move as the start of a bigger breakout, while skeptics warn long-time holders could sell heavily into that level, which has capped previous rallies.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is trending as it rips sharply higher toward record highs, with traders piling into 0DTE calls and squeezing bears, a move the community attributes to falling oil prices on hopes of U.S.-Iran de-escalation and positioning ahead of the Trump-Xi summit. Sentiment is split between euphoric momentum buyers and skeptics who call the move an unsustainable, manipulated 'blow-off top' or bull trap.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Reports that Paramount Skydance is in advanced settlement talks with California and other state attorneys general over the antitrust suit blocking its Warner Bros. Discovery merger  with discussed concessions including a large California production commitment, studio-retention guarantees, and CNN oversight provisions  have driven a sharp rally in the shares. Traders are divided between treating the settlement as effectively sealed and skeptics warning that only unconfirmed reports and leaks have surfaced, with no official announcement yet.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET shares are rallying as traders react to the company's Blazar hybrid laser platform winning an ECOC Exhibition industry award, though the community is split between bulls celebrating the recognition and skeptics dismissing it as noise without the production, shipment, and commercial updates management has promised for September.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fate Therapeutics (FATE) Reports Q2 Loss, Tops Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +10.71% and +108.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Monte Rosa Therapeutics (GLUE) Reports Q2 Loss, Misses Revenue Estimates

Monte Rosa Therapeutics (GLUE) delivered earnings and revenue surprises of -72.00% and -65.15%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

S&P 500, Nasdaq, Dow End Higher Led By Chipmaker Stocks As Investors Look Past US-Iran Hostility — ORCL, SBUX, WULF, PANW, FATE In Focus

Equity

The United States carried out a second consecutive day of new military operations against Iran.

FATE Stock Jumps 6% As FDA Greenlights Moving Cell Therapy To Clinical Trials

The clearance allows the company to begin an early-stage basket trial in multiple autoimmune diseases later this year.

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs

A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs PR Newswire NEW YORK, June 30, 2026 Issued on behalf of GT Biopharma, Inc.GT...

The $13 Million Company Teaching the Immune System to Hunt Cancer

The $13 Million Company Teaching the Immune System to Hunt Cancer The $13 Million Company Teaching the Immune System to Hunt Cancer PR Newswire NEW YORK, May 29, 2026 Issued on behalf of GT Biopharma, Inc. (NASDAQ: GTBP)Three drugs in human trials. A platform licensed from one of the world's top...

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets

Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes

Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes PR Newswire SAN FRANCISCO, May 19, 2026 Equity Insider News...

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase

Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth...

Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates

Fate Therapeutics (FATE) delivered earnings and revenue surprises of +10.87% and -25.77%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Fate Therapeutics Inc

Bullish Sentiment

Rising interest rates

Surging bond yields

Oil/energy volatility

Trump/political risk

U.S. investors are navigating a stacked macro backdrop, with the Federal Reserve hiking rates for the first time since July 2023, the 10-year Treasury yield hitting 5.00% - its highest level since 2007 - and oil prices swinging between $94 and $105 a barrel amid the ongoing U.S.-Iran conflict and Saudi pipeline disruptions. What's the biggest risk to your portfolio right now? Vote and explain your reasoning in the comments.

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what&#39;s the biggest risk to your portfolio right now?

Stocktwits

With the Fed hiking rates for the first time since 2023, the 10-year Treasury yield near 5%, and oil prices swinging on the U.S.-Iran conflict, what's the biggest risk to your portfolio right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	-$0.27	--	--	N/A
Q2 '26	-$0.26	-$0.25	2.14%	BEAT
Q1 '26	-$0.28	-$0.26	7.14%	BEAT
Q4 '25	-$0.27	-$0.27	0.16%	BEAT
Q3 '25	-$0.29	-$0.27	7.58%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

FATE Earnings

Upcoming Earnings: Q3 '26

Historical Earnings